Digipharm
Digipharm
Token: DPH


Healthcare Beyond Barriers

ICO dates
Start date:
End date:

Registrated in: Switzerland

Platform: Ethereum
Type: ERC20

PREMIUM ICO

https://digipharm.ch/ Screenshot
Digipharm categories
Health
Video
Digipharm token sale
KYC passing required Yes | Whitelist Yes | Restriction for countries No
Tokens for sale 65,000,000
Token distribution in ICO
65%
65%
Price 1 DPH = 1 USD
Price in PreICO 1 DPH = 1 USD
Acceppting ETH
Digipharm news, social
Digipharm search trends in Google
Random whitepaper excerpts

Table of contents
List of figures
03
Disclaimer
04
Abbreviations
05
Terms
06
Abstract
07
Executive summary
08
01
A paradigm shift in healthcare
10
1.1 Innovative pricing and value-based healthcare
10
1.2 Personalised medicine
10
1.3 Data security & privacy
11
02
Innovative pricing
12
2.1 The requirement for innovative pricing solutions
12
2.2 Types of innovative pricing solutions
13
2.3 Current infrastructural limitations to innovative pricing
15
2.4 Accelerated access
19
2.5 Genomic profiling
20
03
Reimburse
21
3.1 The platform
21
3.2 Wider application of the reimburse platform
23
3.3 Stakeholder benefits of the Reimburse platform
24
3.4 Market potential
26
04
Insights
27
4.1 The requirement for real world evidence
27
4.2...

05
Pipeline projects
34
5.1 MyHealth, incentivizing patients for superior outcomes
34
5.2 Evolve, supporting early medical innovation
35
06
Technological considerations
36
6.1 Overview
36
6.2 Potential for further development
36
6.3 Blockchain technology & smart contract application
37
6.4 Benefits of using the Ethereum ecosystem
38
6.5 Benefits of using private blockchain technology
38
6.6 Compliance & information governance
39
6.7 Cyber security
39
07
Additional services
42
08
DPH health economy
43
8.1 Health economy stakeholders
43
09
Digipharm tokens (DPH)
46
9.1 DPH token use
46
9.2 DPH token characteristics
47
9.3 DPH token sale information
47
9.4 Funding usage & token distribution
48
9.5 Commitment to charitable causes
48
10
References
...

Disclaimer
This Whitepaper is provided by Digipharm GmbH for informational purposes only. Nothing in
this Whitepaper shall be construed as an offer to sell or buy securities in any jurisdiction, or a
solicitation for investment, or an investment advice. The Whitepaper does not regulate any sale
and purchase of DPH tokens (as referred to in the Whitepaper). The purchase of DPH tokens is
subject to the Token Sale Terms and Conditions and the use of DPH is subject to the Platform
Terms and Policies.
This Whitepaper describes the current vision for the DPH platforms. While we intend to attempt to
realize this vision, please recognize that it is dependent on quite a number of factors and subject
to quite a number of risks. It is entirely possible that platforms will never be implemented or
adopted, or that only a portion of our vision will be realized. We do not guarantee or warrant any
of the statements in this Whitepaper, because they are based on our current beliefs, expectations
and assumptions, abo...

Abbreviations
Acronym
AML
API
FDA
FTC
FINMA
GDPR
HIPAA
HITECH
HITRUST
HTA
ICO
IT
KYC
NHS
RWE
TDABC
VBP
Expansion
Anti money laundering
Application programming interface
Food and Drug Administration
Federal Trade Commission Act
Swiss Financial Market Supervisory Authority
General Data Protection Regulation
Health Insurance Portability and Accountability Act
Health Information Technology for Economic and Clinical Health Act
Health Information Trust Alliance
Health technology assessment
Initial coin offering
Information Technology
Know your customer
National Health Service
Real world evidence
Time driven activity based costing
Value-based pricing
5
DIGIPHARM Whitepaper
[email protected]
www.digipharm.ch
...

Terms
Term
Value-based pricing
Patients
Payers
Manufacturers
Providers
Reimbursement
Definition
Pricing of a service or product according to the benefits it provides
to a consumer
The person receiving medical treatment
The entity responsible for the financial settlement of healthcare
products or services
Typically pharmaceutical companies that are responsible for
developing and marketing therapies
Healthcare professionals that are authorised to practice by the
appropriate regulatory bodies
A situation where a manufacturer is paid for a pharmaceutical
product by the consumer or a third party representing a consumer
6
DIGIPHARM Whitepaper
[email protected]
www.digipharm.ch
...

Abstract
Digipharms’ solutions aim to accelerate the much needed restructuring of healthcare delivery
systems to a value-based approach. The inherent flaws of current global healthcare infrastructure
result in substantial inefficiency, wastage and sub-optimal health outcomes for the most
important stakeholder; the patient. In healthcare today, there is a lack of incentive for health
systems and providers to focus on mutually beneficial collaboration and the maximisation of
patient outcomes.
Digipharm aims to utilise innovative blockchain technology to overcome barriers to
patient access and innovative pricing, reduce costs for all stakeholders, and bypass
infrastructural limitations to drive value improvement, incentivise innovation and expedite
the transformation to personalised healthcare.
Digipharms’ vision is to be ‘the pioneer of value-based healthcare delivery,
innovative evidence generation and patient empowerment across the healthcare
industry’ using revolutionary blockchain ...

Executive Summary
Problem
Barriers to innovative pricing and ‘paying for performance’
Healthcare systems are often required to make the difficult decision of whether to reimburse costly
pharmacological therapies and provide access for patients while taking into account their limited
resources. Innovative pricing approaches have the ability to overcome the challenges faced by
healthcare systems when assessing the funding of new drugs, to enable the implementation of
‘flexible’ pricing schemes to assess the price of treatment in relation to the benefits it delivers.
Unfortunately, healthcare systems around the world lack the relevant infrastructure to track
and implement innovative pricing models such as value-based pricing agreements, and so are
reluctant to adopt such innovative policies. This results in novel pharmacological therapies
being denied to patients who are most at need, an opportunity missed to decrease the long
term economic and disease burden on health systems, and a barrier t...

Goals
To remove infrastructural barriers and
automate the implementation of innovative
value-based pricing agreements on a fully
independent platform; in order to facilitate
personalised reimbursement of health
technology on a ‘fee for performance’ basis
for the mutual benefit of patients, payers and
manufacturers.
To develop the world’s first ‘live’ RWE
platform. Allowing the utilisation of real
world data (RWD) as soon as it becomes
available, to inform health related research,
decision making and to incentivise patients
to contribute their data.
Solutions
Reimburse
The Reimburse platform harnesses the benefits of automated ‘smart contracts’ and blockchain
technology; facilitating the application of truly dynamic innovative pricing solutions between
healthcare systems and manufacturers, in a secure and compliant fashion with minimal
administrative burden. Use of the Reimburse platform will expedite integration, coordination
Ahmed Abdulla
Ahmed Abdulla Founder/CEO

Girisha Fernando
Girisha Fernando Co-Founder/COO

Alexander Sverdlov
Alexander Sverdlov Cybersecurity Strategy

Meredith Darden
Meredith Darden Digital Marketing Lead

Alexey Popov
Alexey Popov Web Development

Michael Gubert
Michael Gubert UI/UX Design

Leon Rebolledo
Leon Rebolledo Lead Architect

Rolf Günter
Rolf Günter Legal Counsel

Bobby Kaura
Bobby Kaura Business Development

Mohamed Abdulla
Mohamed Abdulla Clinical Transformation

Hasham Al-Meshhedani
Hasham Al-Meshhedani Patient Engagement

Ali Al-Sudani
Ali Al-Sudani Clinical Pharmacist

Rami Radwan
Rami Radwan Clinical Relations

Peter Sandbach
Peter Sandbach Communications Director

Debra De Silva-Sun
Debra De Silva-Sun HEOR & Pricing Analyst

Marko Granic
Marko Granic Graphic Designer

Sven Möller
Advisors Sven Möller ICO Advisor Swisscom Blockchain AG

Kamal Youssefi
Advisors Kamal Youssefi Enterprise Blockchain Advisor Swisscom Blockchain AG

Waldemar Scherer
Advisors Waldemar Scherer Life Sciences Blockchain Advisor Swisscom Blockchain AG

Sam Mantle
Advisors Sam Mantle Health & Life Sciences Technology Advisor Luxoft

Daniel Heller
Advisors Daniel Heller PR Advisor Partner, Farner Consulting AG

Claudio Staub
Advisors Claudio Staub Co-Head Startup Communications Farner Consulting AG

Anas Aman
Advisors Anas Aman Quality and Testing IBM

Lloyd Jefferies
Advisors Lloyd Jefferies CRM Advisor KPMG

Per-Olof Thuresson
Advisors Per-Olof Thuresson Health Economist Roche

Fadi Chehadah
Advisors Fadi Chehadah Health Economist NICE UK

Alexander Sverdlov
Alexander Sverdlov
Cybersecurity Strategy
Security Adviser
Security Advisor
KYC Compliance Expert
KYC Compliance Expert
Alexey Popov
Alexey Popov
Web Development
Support Team Manager
Daniel Heller
Daniel Heller
PR Advisor Partner, Farner Consulting AG
Meredith Darden
Meredith Darden
Digital Marketing Lead
Senior community representative
Advisor
Sven Moller
Sven Moller
Head of ICO Advisory
Sven Möller
Sven Möller
ICO Advisor Swisscom Blockchain AG
ICO Advisor
Zach Daniels
Zach Daniels
CTO